Comparison of the clinical relevance of CEA, CA 15-3 and MCA in breast cancer

Oncology Research and Treatment

Volumn 19, Issue 2, 1996, Pages 170-174

  Bremer, K ^a   Micus, S ^a   Bremer, G ^a   Eberhard, A ^b  

^a Augusta Kranken Anstalt   (Germany)

^b Gemeinschaftspraxis für Laboratoriums medizin   (Germany)

Author keywords

Breast Cancer; CA 15 3 and MCA; CEA; Clinical relevance

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER EPIDEMIOLOGY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY;

EID: 0029956064     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218785     Document Type: Article

References (11)

1. Gold P, Freedmann SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965; 122:467-481.
2. Zenklusen H-R, Overbeck J von, Stähli C, Gutadt F, Rohling H, Heitz PU: The immunohistochemical reactivity of a new anti-epithelial monoclonal antibody (MAB b-12) against breast carcinoma and other normal and neoplastic human tissues. Virchows Arch [A] 1988;413:3-10.
3. Rasmussen BB. Peterson BV, Thorpe SM, Hilkens J, Hilgers J, Rose J: Prognostic value of surface antigens in primary breast carcinomas, detected by monoclonal antibodies. Cancer Res 1985:45:1424-1428.
4. Ammon A, Eiffert H, Weber MH, Alhusen R, Beyer JH: Tumormarker in der Verlaufskontrolle des metastasierten Mammacarcinoms - Ein Vergleich der tumorassoziierten Antigenc CEA. CA 15-3, MCA, CA 12-5. In vitro Diagnostica Special 1991:2:15-19.
5. Liu Q, Oehr P: CEA, TPS. CA 15-3, CA 27.29 und CA 549 beim Mammacarcinom. In vitro Diagnostica Special 1991:2:14.
6. Steger GG, Mader R, Derfler M, Moser X, Dittrich C: Mucin-like carcinoma-associated antigen (MCA) compared with CA 15.3 in advanced breast cancer. Klin Wochenschr 1989:67:813-817.
7. Ammon A, Eiffert H, Alhusen R, Weber M, Rümelin B, Groh E, Bartsch H, Marschner N, Nagel GA. Krieger G: «Mucin-Like-Carcinoma-Associated Antigen». Sensitivität und Spezifität beim metastasierten Mammacarcinom. Onkologie 1990;13:210-214.
8. Soletcrmos G, Nielsen D, Schioler V, Skovsgaard T, Winkel P, Mouridsen HT, Dombernowsky P: A novel method for monitoring high-risk breast cancer with tumor markers: CA 15-3 compared to CEA and TPA. Ann Oncol 1993:4:861-869.
9. Hayes DF: Tumor markers for breast cancer. Ann Oncol 1993:4:807-819.
10. Yasasever V, Karaloglu D, Erturk N, Dalay N: Diagnostic value of tumor markers in breast cancer. Eur J Gynaecol Oncol 1994:15:33-36.
11. Lamerz R, Stieber P, Fateh-Moghadam A: Serum marker combinations in human breast cancer. In Vivo 1993;7:607-613.